NovoCure
NVCR
356 hedge funds and large institutions have $12.9B invested in NovoCure in 2020 Q4 according to their latest regulatory filings, with 108 funds opening new positions, 119 increasing their positions, 88 reducing their positions, and 33 closing their positions.
227% more first-time investments, than exits
New positions opened: 108 | Existing positions closed: 33
63% more call options, than puts
Call options by funds: $352M | Put options by funds: $215M
58% more capital invested
Capital invested by funds: $8.15B → $12.9B (+$4.71B)
35% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 88
26% more funds holding
Funds holding: 282 → 356 (+74)
0.45% more ownership
Funds ownership: 72.47% → 72.92% (+0.45%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$153M |
| 2 |
State Street
Boston,
Massachusetts
|
+$107M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$56M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$38.2M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$36.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$93M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$84.9M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$80.7M |
| 4 |
DCP
Darsana Capital Partners
New York
|
-$78.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$45M |
NVCR Hedge Fund Activity: Q4 2020 in Review
356 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q4 2020, worth a combined $12.9B — up 58% from $8.15B a quarter earlier.
Buyers outnumbered sellers: 108 funds opened new NVCR positions and 33 closed out — a net gain of 75 holders — while 119 added to existing stakes and 88 trimmed.
The largest buyer was Capital World Investors, adding an estimated $153M. The largest seller was Renaissance Technologies, cutting an estimated $93M.
- 356 institutional investors held NovoCure (NVCR) as of Q4 2020, up from 282 in Q3 2020.
- Funds reported $12.9B of NovoCure stock for Q4 2020, up 58% quarter-over-quarter.
- 108 funds opened new NovoCure positions in Q4 2020 and 33 closed out, a net change of +75 holders.
- The largest NovoCure buyer in Q4 2020 was Capital World Investors, an estimated $153M added.
- The largest NovoCure seller in Q4 2020 was Renaissance Technologies, an estimated $93M sold.
Based on aggregated 13F filings for Q4 2020.